Get the Stockscreener App
8.82
0.23%
-0.02
Upstream Bio Inc stock is traded at $8.82, with a volume of 324.84K.
It is down -0.23% in the last 24 hours and up +35.07% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$8.84
Open:
$8.92
24h Volume:
324.84K
Relative Volume:
1.16
Market Cap:
$463.87M
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-6.8654
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
+2.08%
1M Performance:
+35.07%
6M Performance:
-66.31%
1Y Performance:
+0.00%
1-Day Range:
$8.53
$9.40
1-Week Range:
$7.79
$9.40
52-Week Range:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
8.82 | 463.87M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
Is Upstream Bio Inc (NASDAQ: UPB) A Good Investment Now? - Stocksregister
Wells Fargo & Company MN Invests $149,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
27,017 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Acquired by Barclays PLC - Defense World
MetLife Investment Management LLC Invests $181,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Brokers Offer Predictions for Upstream Bio Q2 Earnings - Defense World
Metric Analysis: Upstream Bio Inc (UPB)’s Key Ratios in the Limelight - DWinneX
Upstream Bio Advances Verekitug in Clinical Trials - TipRanks
Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position - TipRanks
Upstream Bio reports Q1 revenue $566k, consensus $326.25k - TipRanks
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - GlobeNewswire
Transpire Bio Announces R&D and Manufacturing Expansion - The Manila Times
Invesco Ltd. Buys Shares of 15,602 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
1,734 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Legal & General Group Plc - Defense World
JPMorgan Chase & Co. Acquires Shares of 47,792 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
LPL Financial LLC Cuts Stake in Invesco FTSE RAFI Developed Markets ex-U.S. Small-Mid ETF (NYSEARCA:PDN) - Defense World
Geode Capital Management LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Inc’s Banking’s 100-Day Moving Average at 11.87: Will the Stock Break Through? - investchronicle.com
Medical Properties Trust Inc (MPW) Stock: Navigating a Year of Volatility - investchronicle.com
CytomX Therapeutics Inc’s Shares Reel: -10.73% Quarterly Revenue Decline Amid 60.07M Market Cap - investchronicle.com
Philip Morris International Inc (PM) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Upstream Bio: Verekitug, A Longer-Acting Dupixent?Key Data Is Imminent - Seeking Alpha
Corebridge Financial Inc. Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by American Century Companies Inc. - Defense World
Old Dominion Freight Line (NASDAQ:ODFL) Given New $188.00 Price Target at Stifel Nicolaus - Defense World
Chronic Rhinosinusitis with Nasal Polyps Market to Expand Significantly by 2034, States DelveInsight Report | AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis - Barchart.com
Upstream Bio (NASDAQ:UPB) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Amtech Systems, Tesla And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Upstream's IPO Lockup Period Expires, RSLS Partners With Israel-based Motion, PVLA On Watch - RTTNews
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket - Benzinga
Certain Common Stock of Upstream Bio, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2025. - marketscreener.com
Upstream Bio, Inc.’s Lock-Up Period Will Expire on April 9th (NASDAQ:UPB) - Defense World
Charles Schwab Investment Management Inc. Invests $2.23 Million in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Bank of New York Mellon Corp Invests $607,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Severe Asthma Clinical Trials and Studies 2025: EMA, PDMA, FDA - openPR.com
Upstream Bioprocessing Market Size, Industry Demand And Report Insights By 2033 - Straits Research
1,660 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Acquired by US Bancorp DE - Defense World
US Bancorp DE Sells 4,285 Shares of SunOpta Inc. (NASDAQ:STKL) - The AM Reporter
Upstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial Execution - TipRanks
William Blair Lifts Earnings Estimates for Upstream Bio - Defense World
Long UPB: Upstream Bio’s Robust Financials and Clinical Progress Signal Bullish Reversal - Invezz
Upstream Bio’s Financial Results and Strategic Progress - TipRanks
Promising Developments and Strong Financial Position Drive Buy Rating for Upstream Bio, Inc. - TipRanks
Buy Rating for Upstream Bio: Promising Clinical Progress and Unique Drug Candidate Potential - TipRanks
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Form 10-K Upstream Bio, Inc. For: Dec 31 - StreetInsider.com
Upstream Bio, Inc. Completes Enrollment in Phase 2 Trial of Verekitug for Chronic Rhinosinusitis and Raises $293 Million in IPO - Nasdaq
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business ... - Enid News & Eagle
Rhumbline Advisers Invests $275,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
AstraZeneca And GSK Put Spotlight On Nasal Polyps Space - Citeline News & Insights
Upstream Bio to Present at Upcoming March Investor Conferences - GlobeNewswire
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Upstream Bio Inc Stock (UPB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):